Fig. 2: Antibody seroconversion 4 weeks after vector vs. mRNA booster vaccination. | Nature Communications

Fig. 2: Antibody seroconversion 4 weeks after vector vs. mRNA booster vaccination.

From: Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial

Fig. 2

Antibodies to the receptor-binding domain (RBD) of the viral spike (S) protein were determined using an anti-SARS-CoV-2 immunoassay 4 weeks after vaccination. a Anti-RBD antibody levels in patients with (n = 44) and without (n = 2) peripheral B-cells, as indicated by the color of the circles. Dashed line indicates the threshold for seroconversion (0.8 BAU/ml). b Seroconversion rate was calculated based on the presence of anti-RBD antibodies in patients stratified by booster vaccination with vector or mRNA vaccine. c Anti-RBD antibody levels in patients 4 weeks after booster vaccination were correlated with levels of detectable peripheral CD19+ B-cells, with the color of the circles indicating status of seroconversion. Source data are provided as a Source Data file.

Back to article page